Our data suggest that GPC1 is associated with tumor growth and that targeting GPC1 with anti-GPC1 mAb represents a therapeutic strategy to decrease tumor growth in patients with GPC1-positive ESCC. The gene discussed is GPC1; the disease is neoplasm.